BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 38415523)

  • 21. SARS-CoV-2 vaccine antibody response and breakthrough infections in transplant recipients.
    Vanlerberghe B; Vrij C; Bogaerts K; Vermeersch P; Lagrou K; Molenberghs G; Rega F; Ceulemans LJ; van Raemdonck D; Jochmans I; Monbaliu D; Pirenne J; Vanuytsel T; Gillard P; Schoemans H; Cleemput JV; Kuypers D; Vos R; Nevens F; Verbeek J
    J Med Virol; 2023 Apr; 95(4):e28736. PubMed ID: 37185854
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SARS-CoV-2-reactive antibody detection after SARS-CoV-2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group.
    Piñana JL; López-Corral L; Martino R; Montoro J; Vazquez L; Pérez A; Martin-Martin G; Facal-Malvar A; Ferrer E; Pascual MJ; Sanz-Linares G; Gago B; Sanchez-Salinas A; Villalon L; Conesa-Garcia V; Olave MT; López-Jimenez J; Marcos-Corrales S; García-Blázquez M; Garcia-Gutiérrez V; Hernández-Rivas JÁ; Saus A; Espigado I; Alonso C; Hernani R; Solano C; Ferrer-Lores B; Guerreiro M; Ruiz-García M; Muñoz-Bellido JL; Navarro D; Cedillo A; Sureda A;
    Am J Hematol; 2022 Jan; 97(1):30-42. PubMed ID: 34695229
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immune response to vaccination against SARS-CoV-2 in hematopoietic stem cell transplantation and CAR T-cell therapy recipients.
    Wu X; Wang L; Shen L; He L; Tang K
    J Hematol Oncol; 2022 Jun; 15(1):81. PubMed ID: 35710431
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impaired humoral and cellular response to primary COVID-19 vaccination in patients less than 2 years after allogeneic bone marrow transplant.
    Murray SM; Barbanti M; Campbell C; Brown A; Chen L; Dhanapal J; Tseu B; Pervaiz O; Peters L; Springett S; Danby R; Adele S; Phillips E; Malone T; Amini A; Stafford L; Deeks AS; Dunachie S; Klenerman P; Peniket A; Barnes E; Kesavan M
    Br J Haematol; 2022 Aug; 198(4):668-679. PubMed ID: 35655410
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Humoral antibody response following mRNA vaccines against SARS-CoV-2 in solid organ transplant recipients; a status after a fifth and bivalent vaccine dose.
    Christophorou E; Nilsson AC; Petersen I; Lindvig SO; Davidsen JR; Abazi R; Poulsen MK; Pedersen RM; Justesen US; Johansen NE; Bistrup C; Madsen LW; Johansen IS
    Front Immunol; 2023; 14():1270814. PubMed ID: 38090591
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antibody response to a third SARS-CoV-2 vaccine dose in recipients of an allogeneic haematopoietic cell transplantation.
    Bankova AK; Pasin C; Huang A; Cicin-Sain C; Epp S; Audige A; Mueller NJ; Nilsson J; Vilinovszki O; Nair G; Wolfensberger N; Hockl P; Schanz U; Trkola A; Kouyos R; Hasse B; Zinkernagel AS; Manz MG; Abela IA; Müller AMS
    Br J Haematol; 2023 Apr; 201(1):58-63. PubMed ID: 36382698
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cellular and humoral immune responses after a third dose of SARS-CoV-2 mRNA vaccine in lung transplant recipients in Japan.
    Ui M; Hirama T; Akiba M; Honda M; Kikuchi T; Okada Y
    Vaccine; 2023 Jul; 41(31):4534-4540. PubMed ID: 37328349
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
    Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
    Front Immunol; 2022; 13():863554. PubMed ID: 35711445
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serologic Responses following a Single Dose of SARS-Cov-2 Vaccination in Allogeneic Stem Cell Transplantation Recipients.
    Easdale S; Shea R; Ellis L; Bazin J; Davis K; Dallas F; Thistlethwayte E; Ethell M; Potter M; Arias C; Anthias C; Nicholson E
    Transplant Cell Ther; 2021 Oct; 27(10):880.e1-880.e4. PubMed ID: 34293520
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mycophenolate mofetil decreases humoral responses to three doses of SARS-CoV-2 vaccine in liver transplant recipients.
    Meunier L; Sanavio M; Dumortier J; Meszaros M; Faure S; Ursic Bedoya J; Echenne M; Boillot O; Debourdeau A; Pageaux GP
    Liver Int; 2022 Aug; 42(8):1872-1878. PubMed ID: 35338550
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and immunogenicity of a protein subunit COVID-19 vaccine (ZF2001) in healthy children and adolescents aged 3-17 years in China: a randomised, double-blind, placebo-controlled, phase 1 trial and an open-label, non-randomised, non-inferiority, phase 2 trial.
    Gao L; Li Y; He P; Chen Z; Yang H; Li F; Zhang S; Wang D; Wang G; Yang S; Gong L; Ding F; Ling M; Wang X; Ci L; Dai L; Gao GF; Huang T; Hu Z; Ying Z; Sun J; Zuo X
    Lancet Child Adolesc Health; 2023 Apr; 7(4):269-279. PubMed ID: 36803632
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Seroconversion following the first, second, and third dose of SARS-CoV-2 vaccines in immunocompromised population: a systematic review and meta-analysis.
    Mehrabi Nejad MM; Shobeiri P; Dehghanbanadaki H; Tabary M; Aryannejad A; Haji Ghadery A; Shabani M; Moosaie F; SeyedAlinaghi S; Rezaei N
    Virol J; 2022 Aug; 19(1):132. PubMed ID: 35941646
    [TBL] [Abstract][Full Text] [Related]  

  • 33. COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre, prospective, case-control study.
    Alexander JL; Liu Z; Muñoz Sandoval D; Reynolds C; Ibraheim H; Anandabaskaran S; Saifuddin A; Castro Seoane R; Anand N; Nice R; Bewshea C; D'Mello A; Constable L; Jones GR; Balarajah S; Fiorentino F; Sebastian S; Irving PM; Hicks LC; Williams HRT; Kent AJ; Linger R; Parkes M; Kok K; Patel KV; Teare JP; Altmann DM; Goodhand JR; Hart AL; Lees CW; Boyton RJ; Kennedy NA; Ahmad T; Powell N;
    Lancet Gastroenterol Hepatol; 2022 Nov; 7(11):1005-1015. PubMed ID: 36088954
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antibody Response to SARS-CoV-2 Vaccination in Patients following Allogeneic Hematopoietic Cell Transplantation.
    Huang A; Cicin-Sain C; Pasin C; Epp S; Audigé A; Müller NJ; Nilsson J; Bankova A; Wolfensberger N; Vilinovszki O; Nair G; Hockl P; Schanz U; Kouyos RD; Hasse B; Zinkernagel AS; Trkola A; Manz MG; Abela IA; Müller AMS
    Transplant Cell Ther; 2022 Apr; 28(4):214.e1-214.e11. PubMed ID: 35092892
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of mRNA1273 SARS-CoV-2 vaccination in hematopoietic stem cell transplant recipients: Single center experience.
    Huguet M; Boigues M; Sorigué M; Blanco J; Quirant B; Ferrà C; ;
    Med Clin (Barc); 2024 Apr; 162(7):313-320. PubMed ID: 38000941
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [COVID-19 vaccination for allogeneic hematopoietic stem cell recipients].
    Nagafuji K
    Rinsho Ketsueki; 2022; 63(9):1067-1077. PubMed ID: 36198531
    [TBL] [Abstract][Full Text] [Related]  

  • 37. B Cell Aplasia Is the Most Powerful Predictive Marker for Poor Humoral Response after BNT162b2 mRNA SARS-CoV-2 Vaccination in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation.
    Jullien M; Le Bourgeois A; Coste-Burel M; Peterlin P; Garnier A; Rimbert M; Imbert BM; Le Gouill S; Moreau P; Mahe B; Dubruille V; Blin N; Lok A; Touzeau C; Gastinne T; Tessoulin B; Vantyghem S; Béné MC; Guillaume T; Chevallier P
    Transplant Cell Ther; 2022 May; 28(5):279.e1-279.e4. PubMed ID: 35218998
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictors of impaired antibody response after SARS-CoV-2 mRNA vaccination in hematopoietic cell transplant recipients: A Japanese multicenter observational study.
    Mori Y; Uchida N; Harada T; Katayama Y; Wake A; Iwasaki H; Eto T; Morishige S; Fujisaki T; Ito Y; Kamimura T; Takahashi T; Imamura Y; Tanimoto K; Ishitsuka K; Sugita J; Kawano N; Tanimoto K; Yoshimoto G; Choi I; Hidaka T; Ogawa R; Takamatsu Y; Miyamoto T; Akashi K; Nagafuji K
    Am J Hematol; 2023 Jan; 98(1):102-111. PubMed ID: 36260658
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immune Response to SARS-CoV-2 Third Vaccine in Patients With Rheumatoid Arthritis Who Had No Seroconversion After Primary 2-Dose Regimen With Inactivated or Vector-Based Vaccines.
    Isnardi CA; Cerda OL; Landi M; Cruces L; Schneeberger EE; Montoro CC; Alfaro MA; Roldán BM; Gómez Vara AB; Giorgis P; Ezquer RA; Crespo Rocha MG; Reyes Gómez CR; de Los Ángeles Correa M; Rosemffet MG; Abarza VC; Pellet SC; Perandones M; Reimundes C; Longueira Y; Turk G; Quiroga MF; Laufer N; Quintana R; de la Vega MC; Kreplak N; Pifano M; Maid P; Pons-Estel GJ; Citera G
    J Rheumatol; 2022 Dec; 49(12):1385-1389. PubMed ID: 36182107
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antibody response to 2- and 3-dose SARS-CoV-2 mRNA vaccination in pediatric and adolescent kidney transplant recipients.
    Crane C; Phebus E; Ingulli E
    Pediatr Nephrol; 2023 Feb; 38(2):611-614. PubMed ID: 35759003
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.